Dupixent Lawsuits Sought to Be Centralized in Georgia February 23, 2026 Plaintiffs in 15 federal lawsuits involving the prescription drug Dupixent (dupilumab) have asked the Judicial Panel on Multidistrict Litigation (“JPML”) to transfer and consolidate all related cases, spread amongst 9 federal districts, to one federal court. Plaintiffs’ lawsuits allege that, as a result of using Dupixent, they developed cutaneous T-cell lymphoma (CTCL). In February 2026, […] Read More
Trial Date Has Been Set in MDL against Pfizer for Depo-Provera Overseen by Levin Papantonio January 9, 2026 At a Case Management Conference in the multidistrict litigation (MDL) against Pfizer Inc. (NYSE:PFE), the Honorable M. Casey Rodgers set a date for the first trial, which will take place in December 2026, as more than 2,100 women pursue litigation alleging Pfizer failed to adequately warn patients despite long-standing knowledge of the risk. The hearing […] Read More
FDA: Depo-Provera Labels Must Warn of Meningioma Risk December 22, 2025 Labels for Pfizer’s Depo-Provera contraceptive injection must now warn of the risk of meningioma, a type of brain tumor. The U.S. Food and Drug Administration (FDA) required the label change last week. The warning applies to two injectable forms of the drug, Depo-Provera CI and Depo-Subq Provera 104, which consist of progestin, a synthetic form […] Read More
Levin Law
Levin Law